Fundoplication denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for fundoplication are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Fundoplication as "Not FDA-Approved" — and Why This Denial Is Typically Incorrect

Fundoplication is a surgical procedure, not a drug or device requiring FDA marketing approval in the conventional sense. Surgical techniques are generally not subject to pre-market FDA approval the way pharmaceuticals are; rather, the surgical instruments and implantable components used (such as mesh or stapling devices) carry their own clearances. A "not FDA-approved" denial for fundoplication from BCBS most often reflects one of three things: (1) a coding or administrative error that caused the claim to be routed through a drug-approval screening algorithm; (2) a newer technique variant where BCBS is treating the approach as lacking sufficient evidence (effectively an experimental/investigational denial misclassified under a different reason code); or (3) a specific device component used during the procedure that BCBS contends lacks appropriate clearance.

## Why This Denial Is Highly Appealable

Because standard fundoplication is not a drug or biologic, a pure "not FDA-approved" denial based on treatment modality alone is almost certainly a classification error. Identifying the precise basis of the denial — whether it is a coding issue, a technique-evidence issue, or a device issue — is the critical first step. Once the actual basis is clear, the appeal can be targeted and precise.

## Federal Appeal Framework

• Internal appeal — File within the timeframe on your Explanation of Benefits (commonly 180 days). Under ERISA §503, demand the specific basis for the "not FDA-approved" classification in writing, including any policy or technology assessment BCBS relied on.
• Peer-to-peer review — Your surgeon should request an immediate peer-to-peer call with BCBS's medical director to clarify the denial basis; this often resolves misclassified denials before a formal appeal is needed.
• ACA §2719 external review — After an adverse internal decision, an IRO can evaluate whether the denial is consistent with generally accepted clinical practice. Confirm the exact deadline on your denial letter; the standard window is approximately four months.
• Expedited review — Available if delay would seriously jeopardize your health.

## Documentation to Gather

• Surgeon clarification letter — A letter from the operating surgeon specifying the technique, the instruments and devices used (with any applicable FDA clearance numbers for devices), and confirming that the procedure is a standard, established surgical approach.
• BCBS denial basis in writing — The specific policy section, technology assessment, or claim-routing logic BCBS applied; this is essential to drafting an accurate rebuttal.
• Diagnosis and medical-necessity documentation — Records establishing the clinical indication for surgery, in case the denial is a proxy for a medical-necessity or experimental objection.
• Professional society guidelines — Generic reference to the relevant surgical or gastroenterological society's support for the procedure for your indication.

## Criteria-Mapping Structure

| Stated Denial Basis | Rebuttal Evidence | |---|---| | FDA approval claimed required | Explanation that fundoplication is a surgical technique, not an FDA-regulated drug or biologic | | Device component clearance questioned | Device clearance documentation from surgeon or manufacturer | | Technique classified as investigational | Professional society guideline reference + surgeon letter | | Each additional basis identified in writing | Specific chart or regulatory documentation |